LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Editas Medicine Inc

Fermé

SecteurSoins de santé

1.61 5.92

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.47

Max

1.61

Chiffres clés

By Trading Economics

Revenu

-31M

-76M

Ventes

-26M

4.7M

BPA

-0.92

Marge bénéficiaire

-1,633.491

Employés

246

EBITDA

17M

-44M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+107.33% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-4.2M

125M

Ouverture précédente

-4.31

Clôture précédente

1.61

Sentiment de l'Actualité

By Acuity

92%

8%

372 / 382 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Editas Medicine Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 mai 2025, 23:25 UTC

Actions en Tendance

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 mai 2025, 21:57 UTC

Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 mai 2025, 21:29 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefónica's Operations in Uruguay

21 mai 2025, 21:01 UTC

Principaux Mouvements du Marché

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 mai 2025, 23:49 UTC

Market Talk

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 mai 2025, 23:37 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 mai 2025, 23:33 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 mai 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 mai 2025, 23:32 UTC

Market Talk
Acquisitions, Fusions, Rachats

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 mai 2025, 23:31 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 mai 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 mai 2025, 23:30 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 mai 2025, 23:29 UTC

Acquisitions, Fusions, Rachats

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 mai 2025, 23:28 UTC

Résultats

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 mai 2025, 23:27 UTC

Résultats

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 mai 2025, 23:26 UTC

Résultats

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 mai 2025, 23:23 UTC

Acquisitions, Fusions, Rachats

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 mai 2025, 23:22 UTC

Actualités

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21 mai 2025, 23:22 UTC

Acquisitions, Fusions, Rachats

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 mai 2025, 23:20 UTC

Acquisitions, Fusions, Rachats

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 mai 2025, 23:18 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 mai 2025, 23:04 UTC

Actualités

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21 mai 2025, 21:46 UTC

Actualités

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21 mai 2025, 21:42 UTC

Actualités
Acquisitions, Fusions, Rachats

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 mai 2025, 21:14 UTC

Acquisitions, Fusions, Rachats

Millicom to Acquire Telefónica's Ops in Uruguay

21 mai 2025, 21:07 UTC

Actualités

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 mai 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Comparaison

Variation de prix

Editas Medicine Inc prévision

Objectif de Prix

By TipRanks

107.33% hausse

Prévisions sur 12 Mois

Moyen 3.11 USD  107.33%

Haut 5 USD

Bas 1 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

12 ratings

5

Achat

6

Maintien

1

Vente

Score Technique

By Trading Central

1.33 / 1.54Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Neutral Evidence

Long Terme

No Evidence

Sentiment

By Acuity

372 / 382Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Baissières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.